Related Experiment Videos
New trends in non-absorbable antibiotics in gastrointestinal disease
G Di Febo1, C Calabrese, F Matassoni
1Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
Abstract:
Numerous antibiotics have been used for several years in the treatment of intestinal diseases, the majority belonging to the class of aminoglycosides. These are effective against gram-positive and some gram-negative bacteria, above all aerobes, and do not therefore cover the entire range of microorganisms responsible for intestinal infections. With these antibiotics, moreover, it is not possible to exclude intestinal absorption which can lead to serious side effects. Other intestinal antibiotics, however, such as Vancomycin, have a restricted spectrum of action which limits their use. This study analyzes the pharmacological characteristics of a new non-absorbable antibiotics with particularly interesting properties from a clinical pharmacokinetic and pharmacodynamic point of view: Rifaximin. This drug has an extremely broad spectrum of action covering all intestinal germs, and its absorption is practically zero. The results of some controlled clinical studies in gastrointestinal diseases are examined, such as the treatment of infectious diarrhoea, of acute or chronic portal-caval encephalopathy and of diverticular disease of the colon. The possible role of Rifaximin in some intestinal diseases, such as small bowel bacterial overgrowth and Crohn's disease and ulcerative colitis, is also analyzed.
Insights
Rifaximin, a non-absorbable antibiotic, offers a broad spectrum of action against intestinal infections with minimal absorption. Clinical studies show its effectiveness in treating various gastrointestinal diseases.
Area of Science:
- Pharmacology
- Microbiology
- Gastroenterology
Background:
- Aminoglycosides and Vancomycin are common intestinal antibiotics but have limitations.
- Aminoglycosides have a narrow spectrum and risk of absorption.
- Vancomycin has a restricted spectrum of action.
Purpose of the Study:
- To analyze the pharmacological characteristics of Rifaximin.
- To evaluate Rifaximin's clinical pharmacokinetic and pharmacodynamic properties.
- To review Rifaximin's efficacy in treating gastrointestinal diseases.
Main Methods:
- Review of pharmacological data.
- Analysis of controlled clinical studies.
- Examination of pharmacokinetic and pharmacodynamic profiles.
Main Results:
- Rifaximin demonstrates a broad spectrum of action against intestinal bacteria.
- Rifaximin exhibits negligible intestinal absorption, reducing side effect risks.
- Clinical studies indicate efficacy in infectious diarrhea, portal-caval encephalopathy, and diverticular disease.
Conclusions:
- Rifaximin is a promising non-absorbable antibiotic for intestinal infections.
- Its broad spectrum and safety profile make it suitable for various GI conditions.
- Further investigation into its role in small bowel bacterial overgrowth and inflammatory bowel diseases is warranted.